Biological markers in superficial bladder tumors and their prognostic significance

Urologic Clinics of North America

Volumn 27, Issue 1, 2000, Pages 179-189

  Zlotta, Alexandre R ^b   Schulman, Claude C ^b  

^a ERASME HOSPITAL   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROTEIN P21; PROTEIN P53; TUMOR MARKER;

ANTIGEN EXPRESSION; BLADDER CANCER; CANCER GROWTH; CANCER IMMUNOTHERAPY; HUMAN; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0033951911     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70246-9     Document Type: Article

References (56)

1. R. Abdel-Fattah C. Challen T.R. Griffiths Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: High frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis Br J Cancer 77 1998 2230 2238
2. T. Asakura Y. Takano M. Iki Prognostic value of Ki67 for recurrence and progression of superficial bladder cancer J Urol 158 1997 385 388
3. WAF1 and p53 expression in breast carcinoma: An immunohistochemical study in 261 patients with long-term follow-up Clin Cancer Res 2 1996 1591 1599
4. M. Caliskan L.N. Turkeri B. Mansuroglu Nuclear accumulation of mutant p53 protein: A possible predictor of failure of intravesical therapy in bladder cancer Br J Urol 79 1997 373 377
5. D.A. Carson A. Lois Cancer progression and p53 Lancet 346 1995 1009 1011
6. G. Casetta P. Gontero R. Russo p53 expression compared with other prognostic factors in OMS grade 1 stage Ta transitional cell carcinoma of the bladder Eur Urol 32 1997 229 236
7. G. Cattoretti M. Becker G. Key Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB 3) detect proliferating cells in microwaved-processed formalin-fixed paraffin sections J Pathol 168 1992 357 363
8. S. Clasen W.A. Schulz C.D. Gerharz Frequent and heterogeneous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma Br J Cancer 4 1998 515 521
9. C. Cordon-Cardo G. Dalbagni G.T. Saez p53 mutations in human bladder cancer: Genotypic versus phenotypic patterns Int J Cancer 56 1994 347 353
10. C. Cordon-Cardo Z.F. Zhang G. Dalbagni Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors Cancer Res 57 1997 1217 1221
11. C. Cordon-Cardo V.E. Reuter Alterations of tumor suppressor genes in bladder cancer Semin Diagn Pathol 14 1997 123 132
12. C. Deng P. Zhang J. Harper Mice lacking p21 cip1/waf1 undergo normal development, but are defective in G1 checkpoint control Cell 82 1995 675 684
13. W. El-Deiry J. Harper P. O'Connor WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis Cancer Res 54 1994 1169 1174
14. R.M. Elledge Assessing p53 status in breast cancer prognosis: Where should you put the thermometer if you think your p53 is sick? J Natl Cancer Inst 88 1996 141 142
15. D. Esrig D. Elmajian S. Groshen Accumulation of nuclear p53 and tumor progression in bladder cancer N Engl J Med 331 1994 1259 1264
16. D. Fontana M. Bellina F. Galietti Intravesical bacillus Calmette-Guérin (BCG) as inducer of tumor-suppressing proteins p53 and p21 J Urol 162 1999 225 230
17. R. Gardiner M. Walsh A. Rahman Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression Br J Urol 73 1994 526 532
18. H.B. Grossman M. Liebert M. Antelo p53 and RB expression predict progression in T1 bladder cancer Clin Cancer Res 4 1998 829 834
19. K. Ick M. Schultz P. Stout Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guérin treatment Urology 49 1997 541 547
20. E.W. Kay C.J. Barry Walsh D. Whelan Interobserver variation of p53 immunohistochemistry—an assessment of a practical problem and comparison with other studies Br J Biomed Sci 53 1996 101 107
21. P.E. Keegan C. Lunec D.E. Neal p53 and p53–regulated genes in bladder cancer Br J Urol 82 1998 710 720
22. L. Lacombe G. Dalbagni Z.F. Zhang Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: Correlation to clinical outcome J Clin Oncol 14 1996 2646 2652
23. L. Lacombe I. Orlow D. Silver Analysis of p21 waf1/cip1 in primary bladder tumors Oncol Res 8 1996 409 414
24. D.P. Lane p53, guardian of the genome Nature 358 1992 15 16
25. S.H. Landis T. Murray S. Bolden Cancer statistics, 1998 CA Cancer J Clin 48 1998 6 29
26. T. Lebret V. Becette M. Barbagelatta Correlation between p53 overexpression and response to bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer J Urol 159 1998 788 791
27. E. Lee I. Park C. Lee Prognostic markers of intravesical bacillus Calmette-Guerin therapy for multiple, high-grade, stage T1 bladder cancers Int J Urol 4 1997 552 556
28. P. Lipponen S. Aaltomaa M. Eskelinen Expression of p21 (WAF1/CIP1) protein in transitional cell bladder tumours and its prognostic value Eur Urol 34 1998 237 243
29. P. Lipponen M. Eskelinen Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis Br J Cancer 69 1994 1120 1125
30. P.K. Lipponen Over-expression of p53 nuclear oncoprotein in transitional cell bladder cancer and its prognostic value Int J Cancer 53 1993 365 370
31. S.B. Malkowicz J.E. Tomaszewski A.J. Linnenbach Novel p21 waf1/cip1 mutations in superficial and invasive transitional cell carcinomas Oncogene 13 1996 1831 1837
32. P.U. Malmstrom H. Wijkstrom C. Lundholm 5-Year follow-up of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma: Swedish-Norwegian Bladder Cancer Study Group J Urol 161 1999 1124 1127
33. A. Marchetti C. Doglioni M. Barbareschi p21 RNA and protein expression in non–small lung carcinomas: Evidence of p53-independent expression and association with tumoral differentiation Oncogene 12 1996 1319 1324
34. P. Michieli M. Chedid D. Lin Induction of WAF1/CIP1 by a p53-independent pathway Cancer Res 54 1994 3391 3395
35. L. Nakopoulou C. Constantinides J. Papandropoulos Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: Comparison with DNA ploidy Urology 46 1995 334 340
36. L. Nakopoulou C. Vourlakou A. Zervas The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates Hum Pathol 29 1998 146 154
37. H. Ovesen T. Horn K. Steven Long-term efficacy of intravesical bacillus Calmette-Guérin for carcinoma in situ: Relationship of progression to histological response and p53 nuclear accumulation J Urol 157 1997 1655 1659
38. F. Pages T.A. Flam A. Vieillefond p53 status does not predict initial clinical response to bacillus Calmette-Guérin therapy in T1 bladder tumors J Urol 159 1998 1079 1084
39. C. Pfister F. Buzelin C. Casse Comparative analysis of MiB1 and p53 expression in human bladder tumors and their correlation with cancer progression Eur Urol 33 1998 278 284
40. C. Pfister J.M. Flaman F. Dunet p53 mutations in bladder tumors inactivate the transactivation of the p21 and BAX genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guérin therapy J Urol 162 1999 69 73
41. Z. Popov A. Hoznek M. Colombel The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder Cancer 80 1997 1472 1481
42. M.P. Raitanen T.L. Tammela M. Kallioinen p53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer J Urol 157 1997 1250 1253
43. A. Sarkis G. Dalbagni C. Cordon-Cardo Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder J Urol 152 1994 388 392
44. A.S. Sarkis Z.F. Zhang C. Cordon-Cardo p53 nuclear overexpression and disease progression in Ta bladder carcinoma Int J Oncol 3 1993 355 360
45. J. Serth M.A. Kuczyk C. Bokemeyer p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder Br J Cancer 71 1995 201 205
46. M.S. Sheikh S.X. Li Z.M. Shao Mechanisms of regulation of WAF1/CIP1 gene expression in human breast carcinoma: Role of p53-dependent and independent signal transduction pathways Oncogene 9 1994 3407 3414
47. N.E. Stavropoulos E. Loackim-Velogianni K. Hastazeris Growth fractions in bladder cancer defined by Ki67: Association with cancer grade, category and recurrence rate of superficial lesions Br J Urol 72 1993 736 739
48. J.P. Stein D.A. Ginsberg G.D. Grossfeld Effect of p21 waf1/cip1 expression on tumor progression in bladder cancer J Natl Cancer Inst 90 1998 1072 1079
49. B. Tetu Y. Fradet P. Allard Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer J Urol 155 1996 1784 1788
50. D.J. Thomas M.C. Robinson R. Charlton p53 expression, ploidy and progression in p1 transitional cell carcinoma of the bladder Br J Urol 73 1994 533 537
51. M.A. Underwood J. Reeves G. Smith Overexpression of p53 protein and its significance for recurrent progressive bladder tumours Br J Urol 77 1996 659 666
52. J.A. Vet J.A. Witjes S.A. Marras Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer Clin Cancer Res 2 1996 1055 1061
53. S. Waga G.J. Hannon D. Beach The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA Nature 369 1994 574 578
54. C. Wright D. Thomas K. Mellon Expression of retinoblastoma gene product and p53 protein in bladder carcinoma: Correlation with Ki67 index Br J Urol 75 1995 173 179
55. Y. Yin M.A. Tainski F.Z. Bischoff Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p 53 alleles Cell 70 1992 937 948
56. A.R. Zlotta J.C. Noel I. Fayt Correlation and prognostic significance of p53, p21 waf1/cip1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy J Urol 161 1999 792 798